Blog
RSS FeedPosted by Michael Wonder on 03 Jun 2016
NICE publishes appraisal consultation for crizotinib (Xalkori) for patients with non-small-cell lung cancer
1 June 2016 - NICE has published an appraisal consultation document for crizotinib (Xalkori) for use by patients with non-small-cell ...
Posted by Michael Wonder on 03 Jun 2016
NICE publishes appraisal consultation for pirfenidone (Esbriet) for patients with idiopathic pulmonary fibrosis
3 June 2016 - NICE has published an appraisal consultation document for pirfenidone (Esbriet) for use by patients with idiopathic ...
Posted by Michael Wonder on 02 Jun 2016
Proposal for the supply of influenza vaccine
2 June 2016 - Following a request for proposals for the supply of influenza vaccine, issued on 3 February 2016, PHARMAC ...
Posted by Michael Wonder on 02 Jun 2016
Cobimetinib in advanced melanoma with BRAF V600 mutation: added benefit now considerable
2 June 2016 - New analyses from the commenting procedure showed further advantages of the drug. ...
Posted by Michael Wonder on 02 Jun 2016
Agenda for the 8 June 2016 TC meeting
1 June 2016 - The Transparency Commission will consider the (continued) reimbursement of dexketoprofen with tramadol hydrochloride (Skudexum), empagliflozin (Jardiance), plasma ...
Posted by Michael Wonder on 01 Jun 2016
NICE to research patient preferences in HTA
1 June 2016 - Myeloma UK has awarded a health services research grant to NICE, to fund an exploratory study on ...
Posted by Michael Wonder on 01 Jun 2016
The challenge of costly drugs
2 June 2016 - From June 2005 to June 2014 the annual cost of the PBS rose from $6 billion to ...
Posted by Michael Wonder on 01 Jun 2016
Ramucirumab in colorectal and lung cancer: some additional benefits, some reductions in benefits
1 June 2016 - Germany's IQWiG has just completed its assessment of Lilly's Cyramza for patients with colorectal cancer or ...
Posted by Michael Wonder on 01 Jun 2016
NICE asks company to put leukaemia drug forward for new Cancer Drugs Fund
1 June 2016 - NICE has published a second appraisal consultation document for ibrutinib for chronic lymphocytic leukaemia. ...
Posted by Michael Wonder on 01 Jun 2016
PBS palliative care schedule
1 June 2016 - As part of the post-market review of Authority Required PBS listings, the restrictions for a number of ...
Posted by Michael Wonder on 31 May 2016
Schedule of Pharmaceutical Benefits - 1 June 2016 update
1 June 2016 - The June 2016 issue of the Schedule is out and now in effect. ...
Posted by Michael Wonder on 31 May 2016
New Zealand Pharmaceutical Schedule - 1 June 2016 update
1 June 2016 - The June 2016 update to the New Zealand Pharmaceutical Schedule sees the listing of one new medicine. ...
Posted by Michael Wonder on 30 May 2016
Proposals to widen funding access to important vaccines
30 May 2016 - PHARMAC is asking the public for feedback on proposals to widen funding access to the varicella (chickenpox) ...
Posted by Michael Wonder on 26 May 2016
CADTH Common Drug Review and pan-Canadian Oncology Drug Review engagement with the pan-Canadian Pharmaceutical Alliance
26 May 2016 - CADTH is engaging with the pan-Canadian Pharmaceutical Alliance office (pCPA), and effective immediately will be including the ...
Posted by Michael Wonder on 26 May 2016
New Zealand budget 2016: extra $2.2 billion pumped into health
26 May 2016 - An extra $2.2 billion will be pumped into health over four years to help cope with an ...